IAG’s Imaging Expert Team Discuss Psoriatic Arthritis – Clinical Development Insights
Join Dr. Olga Kubassova, Prof. Mikael Boesen, and Prof. Philip Mease during a live webinar to discuss how medical imaging can support targeted patient selection and more precise, objective assessment of the treatment impact.
If you are interested in receiving a replay link, please email email@example.com
About the Webinar:
One of the challenges in treatment of patients with Psoriatic Arthritis (PsA) is the disease’s variable presentation. PsA may present in several clinical domains, including synovitis, dactylitis, skin disease, nail disease, spine disease (spondylitis) and each of these domains has subtly different immunologic pathophysiology drivers. Thus, drug developers may find that their new therapies do very well in individual patients or within some of the domains. Medical Imaging, quantitative biomarkers coupled with efficiencies of modern scanners can support targeted patient selection and more precise objective assessment of the treatment impact.
Key discussion points:
- How can we assess a new treatment efficacy through a clinical trial designed to give us a new comprehensive understanding of the treatment’s impact?
- Are there biomarkers and imaging techniques which can help differentiate patients early?
- State-of-the-art and emerging imaging techniques in trials of psoriatic arthritis
- Imaging biomarkers – in patient selection and efficacy assessment of new treatments targeting PsA
About Dr. Olga Kubassova:
Mathematician and computer scientist with 10+ years expertise in actively managing innovation in life science companies. Scientific interests are in quantitative imaging, development of novel efficacy methodologies, AI, Machine Learning in clinical trials.
About Prof. Mikael Boesen:
Mikael Boesen is currently employed as professor of radiology with focus on musculoskeletal imaging, and head of the musculoskeletal imaging and research at Copenhagen University and Bispebjerg and Frederiksberg Hospital in the Capital region of Denmark. He has 20 years hands-on international experience in clinical research in inflammatory and degenerative joint diseases and serves as a global PI and speaker as well as author of 120+ articles, 6 book chapters and 160 abstracts and he has served as supervisor of more than 20 PhD students and postdocs. He also brings together cross-therapeutic area expertise into MSK imaging from previous work in immuno-oncology and cardiac imaging and he currently spearheads implementation of artificial intelligence into radiological image analysis in Denmark, EU the US all of which he uses to helps drug developers and biotech companies to think outside the box when it comes to designing clinical trials and selecting appropriate imaging strategy within many therapeutic areas
About Prof. Philip Mease:
Dr. Mease is an international key opinion leader, researcher, educator and clinician who cares for patients at Seattle Rheumatology Associates, directs the rheumatology research division at Swedish Medical Center/Providence St. Joseph Health and is Clinical Professor of Medicine at the University of Washington in Seattle. His research interests include psoriatic arthritis and spondyloarthritis, rheumatoid arthritis, osteoarthritis, fibromyalgia and osteoporosis. He is a reviewer for multiple journals including New England Journal of Medicine, Lancet, Arthritis & Rheumatology, Arthritis Care & Research, Annals of the Rheumatic Diseases, The Journal of Rheumatology, and Seminars in Arthritis and Rheumatism. He is a past president and founding organizer of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), active contributor to Outcome Measures in Rheumatology Clinical Trials (OMERACT) research group and serves in an educational and advisory role for the FDA.
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com